CN105055352A - Trimetazidine hydrochloride tablets and preparation method thereof - Google Patents
Trimetazidine hydrochloride tablets and preparation method thereof Download PDFInfo
- Publication number
- CN105055352A CN105055352A CN201510490401.4A CN201510490401A CN105055352A CN 105055352 A CN105055352 A CN 105055352A CN 201510490401 A CN201510490401 A CN 201510490401A CN 105055352 A CN105055352 A CN 105055352A
- Authority
- CN
- China
- Prior art keywords
- trimetazidine hydrochloride
- hydrochloride tablets
- tablets
- healthy
- trimetazidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960001177 trimetazidine Drugs 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000945 filler Substances 0.000 claims abstract description 9
- 239000000080 wetting agent Substances 0.000 claims abstract description 9
- 239000011230 binding agent Substances 0.000 claims abstract description 8
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 15
- 235000010489 acacia gum Nutrition 0.000 claims description 9
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920003081 Povidone K 30 Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicine and particularly relates to trimetazidine hydrochloride tablets and a preparation method thereof. The trimetazidine hydrochloride tablets are prepared from raw materials as follows: trimetazidine hydrochloride, filler, a binder, a lubricant and a wetting agent. The trimetazidine hydrochloride tablets solve the problems of poor compressibility and difficulty in forming of the trimetazidine hydrochloride as the raw material. The invention further provides the preparation method of the trimetazidine hydrochloride tablets. The compressibility of the prepared trimetazidine hydrochloride tablets is improved, the trimetazidine hydrochloride tablets are formed easily, the use value of the trimetazidine hydrochloride tablets can be increased better, trimetazidine hydrochloride is prepared into tablets to facilitate taking of a patient, pain of the patient can be relieved timely, the process is simple, the quality is stable, a production process meets the requirement of GMP (Good Manufacture Practice of Drugs), and the trimetazidine hydrochloride tablets and the preparation method are applicable to industrial mass production.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of Trimetazidine Hydrochloride Tablets in healthy and preparation method thereof.
Background technology
Trimetazidine Hydrochloride Tablets in healthy is clinical is applicable to arteria coronaria functional defect, angina pectoris, the angina pectoris that hemodynamics drug treatment alone is invalid, diabetic coronary artery disease, old myocardial infarction etc.Trimetazidine Hydrochloride Tablets in healthy belongs to other class antianginal cardiovascular drugses; trimetazidine is by the energy metabolism of Cell protection under anoxia or ischemia; stop the decline of intracellular ATP levels; thus ensure that the normal function of ionic pump and the normal operation of permeable membrane sodium-potassium stream, maintain the stable of intracellular environment.Zooscopy finds: trimetazidine: help to maintain heart and the energy metabolism of neural sensation organ in ischemia and hypoxia situation.The change of the permeable membrane ion flow reducing intracellular acidosis and caused by ischemia.While this effect of generation, hematodinamics is had no significant effect.Its curative effect is reliable, and side effect is little, toleration.The Trimetazidine Hydrochloride Tablets in healthy of auspicious positive pharmaceutical manufacturing enjoys a good market both at home and abroad market, relieves slight illness to countless patient.Also good economic benefit and social benefit is achieved.
Angina pectoris is coronary insufficiency, cardiac muscle sharply, caused by ischemia and anoxia be the clinical syndrome of main manifestations with ictal chest pain or chest discomfort.Update shows, and China's cardiovascular patient prevalence is in lasting ascent stage, reaches 2.3 hundred million before ill total number, on average just has 1 people to suffer from heart disease in every 5 adults.The patient that cardiovascular diseases's disease is died from the whole nation every year has 3,500,000.The paathogenic factor that to be all the cardiovascular risk factors of generally acknowledging at present the be cardiovascular disease such as smoking, diabetes, hypertension, obesity, hyperlipidemia is important, along with the increase of living-pattern preservation and operating pressure, cardiovascular patient prevalence is in lasting ascent stage.
Summary of the invention
Bad for existing Trimetazidine Hydrochloride compressibility, the shortcoming that molding is more difficult, the object of this invention is to provide a kind of Trimetazidine Hydrochloride Tablets in healthy, compressibility strengthens, easy-formation, better can improve the use value of Trimetazidine Hydrochloride Tablets in healthy, the present invention also provides its preparation method, technique is simple, steady quality.
A kind of Trimetazidine Hydrochloride Tablets in healthy, be made up of the raw material of following parts by weight:
Trimetazidine Hydrochloride 2.2-2.4 part, filler 6.0-6.2 part, binding agent 0.4-0.5 part, lubricant 0.3-0.4 part and wetting agent 1.2-1.4 part.
Wherein:
Binding agent is selected from ethyl cellulose, PVP K30, one or more in polyethylene glycol 6000, methylcellulose or hypromellose; Binding agent effectively can play adhesive effect, adds compressibility.
Filler be selected from starch, pregelatinized Starch, lactose, microcrystalline Cellulose, dextrin or mannitol one or more.
Lubricant be selected from Pulvis Talci, magnesium stearate, silicon dioxide or Stepanol MG one or more.
Wetting agent is selected from one or more of arabic gum alcoholic solution or tragakanta alcoholic solution.Wherein: it is 20% arabic gum alcoholic solution that arabic gum alcoholic solution is preferably concentration; Tragakanta alcoholic solution is preferably the tragakanta alcoholic solution that concentration is 20%.
The preparation method of described Trimetazidine Hydrochloride Tablets in healthy, is prepared by following preparation method:
(1) Trimetazidine Hydrochloride is crossed 22 order mesh screens;
(2) Trimetazidine Hydrochloride, filler and binding agent mix homogeneously that step (1) obtains is taken;
(3) add wetting agent, granulate with 18 order mesh screens, dry, granulate;
(4) add lubricant always mixed rear tabletting, obtain Trimetazidine Hydrochloride Tablets in healthy.
The present invention adopts effective ingredient and special solid preparation adjuvant to prepare Trimetazidine Hydrochloride Tablets in healthy, and adopt filler and wetting agent synergism, filler brings out cohesive through wetting agent, adds compressibility; Lubricant adds the mobility of granule simultaneously, indirectly adds compressibility.
The invention solves the problem that the compressibility of Trimetazidine Hydrochloride is poor, make Trimetazidine Hydrochloride make tablet easily, be conducive to playing its therapeutic effect.
The present invention compared with prior art, has following beneficial effect:
(1) the invention solves raw material Trimetazidine Hydrochloride compressibility bad, the shortcoming that molding is more difficult, Trimetazidine Hydrochloride Tablets in healthy compressibility prepared by the present invention strengthens, easy-formation, better can improve the use value of Trimetazidine Hydrochloride Tablets in healthy, making tablet facilitates patient to take, and is conducive to removing patient's slight illness in time.
(2) Trimetazidine Hydrochloride Tablets in healthy preparation method technique of the present invention is simple, steady quality, and production process meets the requirement of GMP, is applicable to industrialized great production.
(3) Trimetazidine Hydrochloride Tablets in healthy that prepared by the present invention is conducive to giving full play to Trimetazidine Hydrochloride Tablets in healthy therapeutical effect, can be used for the prophylactic treatment of angina pectoris attacks, the complementary symptomatic treatment of dizzy and tinnitus, this medicine is the stronger anti-anginal drug of effect, and the persistent period is longer.There is the effect to antiadrenergic drug, norepinephrine and vassopressin, can vascular resistance be reduced, increase coronary flow and surrounding loop blood flow, promote the generation of myocardial metabolism and cardiac energy.Heart working load can be lowered simultaneously.Reduce the consumption of myocardial oxygen consumption and cardiac energy, thus improve the equilibrium of supply and demand of myocardium oxygen.Still can increase the toleration to cardiotonic glycoside.
Detailed description of the invention
Below in conjunction with embodiment, the present invention will be further described.
Embodiment 1
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.2kg Trimetazidine Hydrochloride, 2.8kg microcrystalline Cellulose, 3.4kg pregelatinized Starch and 0.4kg polyethylene glycol 6000 mix homogeneously is taken by prescription.Add the tragakanta alcoholic solution that 1.3kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.3kg Stepanol MG and 0.1kg magnesium stearate always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 2
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.4kg Trimetazidine Hydrochloride, 2.7kg mannitol, 3.3kg lactose and 0.5kg methylcellulose mix homogeneously is taken by prescription.Add the arabic gum alcoholic solution that 1.4kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.15kg silicon dioxide and 0.15kg Pulvis Talci always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 3
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.3kg Trimetazidine Hydrochloride, 2.9kg dextrin, 3.2kg lactose and 0.4kg hypromellose mix homogeneously is taken by prescription.Add the arabic gum alcoholic solution that 1.2kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.1kg Stepanol MG and 0.2kg Pulvis Talci always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 4
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.2kg Trimetazidine Hydrochloride, 2.4kg starch, 3.6kg dextrin and 0.5kg ethyl cellulose mix homogeneously is taken by prescription.Add the tragakanta alcoholic solution that 1.3kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.2kg Stepanol MG and 0.1kg silicon dioxide always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 5
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.4kg Trimetazidine Hydrochloride, 6.1kg microcrystalline Cellulose and 0.4kg PVP K30 mix homogeneously is taken by prescription.Add the arabic gum alcoholic solution that 1.4kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.3kg magnesium stearate always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
According to the relevant regulations of national Bureau of Drugs Supervision standard YBH13562005 and CP2010, detect the product that embodiment 1-5 prepares, concrete outcome is in table 1.
The testing result of the product that table 1 embodiment 1-5 prepares
| Sample source | Dissolution | Weight differential | Hardness | Friability | Disintegration |
| Embodiment 1 | 98％ | 2.3％ | 112.7N | 0.49％ | 6.5min |
| Embodiment 2 | 99％ | 3.5％ | 124.1N | 0.43％ | 5.7min |
| Embodiment 3 | 97％ | 4.1％ | 131.4N | 0.34％ | 6.2min |
| Embodiment 4 | 101％ | 3.3％ | 119.3N | 0.38％ | 5.2min |
| Embodiment 5 | 100％ | 3.2％ | 109.9N | 0.51％ | 6.0min |
Claims (8)
1. a Trimetazidine Hydrochloride Tablets in healthy, is characterized in that: be made up of the raw material of following parts by weight:
Trimetazidine Hydrochloride 2.2-2.4 part, filler 6.0-6.2 part, binding agent 0.4-0.5 part, lubricant 0.3-0.4 part and wetting agent 1.2-1.4 part.
2. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: binding agent is selected from ethyl cellulose, PVP K30, one or more in polyethylene glycol 6000, methylcellulose or hypromellose.
3. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: filler be selected from starch, pregelatinized Starch, lactose, microcrystalline Cellulose, dextrin or mannitol one or more.
4. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: lubricant be selected from Pulvis Talci, magnesium stearate, silicon dioxide or Stepanol MG one or more.
5. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: wetting agent is selected from one or more of arabic gum alcoholic solution or tragakanta alcoholic solution.
6. Trimetazidine Hydrochloride Tablets in healthy according to claim 5, is characterized in that: arabic gum alcoholic solution is concentration is 20% arabic gum alcoholic solution.
7. Trimetazidine Hydrochloride Tablets in healthy according to claim 5, is characterized in that: tragakanta alcoholic solution to be concentration be 20% tragakanta alcoholic solution.
8. a preparation method for the arbitrary described Trimetazidine Hydrochloride Tablets in healthy of claim 1-7, is characterized in that: be prepared by following preparation method:
(1) Trimetazidine Hydrochloride is crossed 22 order mesh screens;
(2) Trimetazidine Hydrochloride, filler and binding agent mix homogeneously that step (1) obtains is taken;
(3) add wetting agent, granulate with 18 order mesh screens, dry, granulate;
(4) add lubricant always mixed rear tabletting, obtain Trimetazidine Hydrochloride Tablets in healthy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510490401.4A CN105055352A (en) | 2015-08-11 | 2015-08-11 | Trimetazidine hydrochloride tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510490401.4A CN105055352A (en) | 2015-08-11 | 2015-08-11 | Trimetazidine hydrochloride tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055352A true CN105055352A (en) | 2015-11-18 |
Family
ID=54485038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510490401.4A Pending CN105055352A (en) | 2015-08-11 | 2015-08-11 | Trimetazidine hydrochloride tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105055352A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434380A (en) * | 2015-12-11 | 2016-03-30 | 南京正科医药股份有限公司 | Trimetazidine dihydrochloride tablet |
| CN111557922A (en) * | 2020-06-28 | 2020-08-21 | 江苏吴中医药集团有限公司 | A kind of trimetazidine hydrochloride preparation and preparation method thereof |
| CN107982231B (en) * | 2018-01-03 | 2021-05-07 | 江苏吴中医药集团有限公司 | Trimetazidine hydrochloride tablet and preparation method thereof |
| CN117797152A (en) * | 2023-12-29 | 2024-04-02 | 海南锦麟医药科技有限公司 | Medicine for protecting cell nourishing myocardial cells and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407801A (en) * | 1980-09-30 | 1983-10-04 | Science Union Et Cie | Anti-ischemic pharmaceutic compositions |
| CN101283992A (en) * | 2008-05-29 | 2008-10-15 | 胡传良 | Trimetazidine hydrochloride dispersible tablet and preparation method thereof |
| CN103239417A (en) * | 2012-02-13 | 2013-08-14 | 瑞阳制药有限公司 | Preparation method of trimetazidine dihydrochloride tablet |
-
2015
- 2015-08-11 CN CN201510490401.4A patent/CN105055352A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407801A (en) * | 1980-09-30 | 1983-10-04 | Science Union Et Cie | Anti-ischemic pharmaceutic compositions |
| CN101283992A (en) * | 2008-05-29 | 2008-10-15 | 胡传良 | Trimetazidine hydrochloride dispersible tablet and preparation method thereof |
| CN103239417A (en) * | 2012-02-13 | 2013-08-14 | 瑞阳制药有限公司 | Preparation method of trimetazidine dihydrochloride tablet |
Non-Patent Citations (1)
| Title |
|---|
| 罗明生 等主编: "《药剂辅料大全》", 31 March 1993, 四川科学技术出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434380A (en) * | 2015-12-11 | 2016-03-30 | 南京正科医药股份有限公司 | Trimetazidine dihydrochloride tablet |
| CN107982231B (en) * | 2018-01-03 | 2021-05-07 | 江苏吴中医药集团有限公司 | Trimetazidine hydrochloride tablet and preparation method thereof |
| CN111557922A (en) * | 2020-06-28 | 2020-08-21 | 江苏吴中医药集团有限公司 | A kind of trimetazidine hydrochloride preparation and preparation method thereof |
| CN117797152A (en) * | 2023-12-29 | 2024-04-02 | 海南锦麟医药科技有限公司 | Medicine for protecting cell nourishing myocardial cells and preparation method thereof |
| CN117797152B (en) * | 2023-12-29 | 2024-10-01 | 海南锦麟医药科技有限公司 | Medicine for protecting cell nourishing myocardial cells and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532666A (en) | Anti-fatigue composition, its formulation and application | |
| WO2022036506A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
| CN101283992A (en) | Trimetazidine hydrochloride dispersible tablet and preparation method thereof | |
| CN101804056A (en) | Compound tablet of pioglitazone hydrochloride, glimepiride and preparation method thereof | |
| JP6479658B2 (en) | Super-fast disintegrating tablet and method for producing the same | |
| JP2019131597A (en) | Super quick decomposition tablet and production method thereof | |
| CN103230594A (en) | Medicine composition of alpha-glucosidase inhibitor and vitamin B | |
| CN101467985B (en) | Bisoprolol fumarate dispersible tablet and preparation method thereof | |
| CN103599140B (en) | Bilobalide controlled release tablet and preparation method | |
| CN103127513A (en) | Alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications | |
| CN107080741A (en) | Pirfenidone sustained release preparation and preparation method | |
| CN106214653A (en) | A kind of FCE-26743A slow releasing tablet and preparation method thereof | |
| WO2017038455A1 (en) | Super-rapid disintegrating tablet, and method for producing same | |
| CN105919991A (en) | Application of euparin to preparation of medicine for treating depression | |
| CN112618504B (en) | Medicinal composition containing erigeron breviscapus extract and borneol and preparation method thereof | |
| CN103919790B (en) | A kind of preparation method of sulfaguanidine-trimethoprim effervescent tablet | |
| JP5982715B2 (en) | Antihypertensive composition | |
| CN104887639B (en) | Trimetazidine Hydrochloride mono-layer osmotic pump controlled release tablets and preparation method | |
| CN101897692B (en) | artificial musk and isosorbide mononitrate compound orally disintegrating tablet and preparation method thereof | |
| CN105193758A (en) | Gliclazide sustained release tablets and preparation method thereof | |
| CN102512391B (en) | Azelnidipine quick-releasing drug preparation and preparation method | |
| CN103381209A (en) | Hawthorne leaf total-flavones sustained-release preparation and preparation method thereof | |
| CN105796514A (en) | Alogliptin benzoate oral disintegrating tablet and preparation method thereof | |
| EP2374457B1 (en) | Antihypertensive pharmaceutical composition | |
| CN101081220A (en) | Angiocardiopathy treating traditional Chinese medicine and the preparing technology thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151118 |